Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital

Drug-related challenges following primary total hip and knee arthroplasty

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

We aimed to characterize the in-hospital analgesic use among total hip or knee arthroplasty (THA or TKA) patients, and to identify possible drug-related challenges. We identified 15 263 patients operated with a THA or TKA between 1 January 2012 and 30 April 2016. The prevalence of analgesic users and patients with potential clinically relevant drug-drug interactions (DDIs), along with the prevalence of readmission among patients with vs. without a DDI, were calculated. A DDI was defined as the combination of (A) a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, and an non-steroidal anti-inflammatory Drug (NSAID); (B) warfarin and an NSAID; and (C) a benzodiazepine or a benzodiazepine-related drug and an opioid. The prevalence of analgesics administered in THA and TKA patients was 99.3% and 99.1% for paracetamol and 93.8% and 98.8% for opioids, respectively. The prevalence of patients who received interaction A, B or C was 8.4%, 2.5% and 40.7%, respectively. Patients with vs. without a DDI had a higher prevalence of 30-day readmission. In conclusion, most THA and TKA patients were administered paracetamol or opioids. The prevalence of 30-day readmission was higher in patients with than in patients without a potential clinically relevant DDI.

TidsskriftBasic & clinical pharmacology & toxicology
Udgave nummer2
Sider (fra-til)139-147
Antal sider9
StatusUdgivet - aug. 2021

ID: 65746339